Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin in Alzheimer's Disease
NCT06391853Withdrawn
- Sponsor
- Erasmus Hospital
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of Generex Oral-lyn in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Erasmus Hospital. Primary endpoints: Effects of INI administration on FMRI data, Effects of INI administration on PET-FDG regional standardized data and 3 more. Planned start Oct 2024; status: withdrawn.
02
Drugs
Generex Oral-lyn
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06391853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391853.